Skip to content

Anti-adhesion Effect of GUARDIX-SGⓇ in Gastric Cancer Surgery

Prospective Multicenter Trial for Anti-adhesion Effect of GUARDIX-SGⓇ Following Radical Gastrectomy in Patients With Gastric Cancer.

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02198898
Enrollment
224
Registered
2014-07-24
Start date
2013-07-31
Completion date
2017-08-31
Last updated
2017-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adhesive Intestinal Obstruction

Brief summary

This study is to evaluate the efficacy of GUARDIX-SGⓇ for patients with gastrectomy in Korea and the investigators hypothesized applying of adhesive preventing agent would reduce incidence of adhesive obstruction after gastrectomy.

Detailed description

Adhesive bowel obstruction is relatively often complication in patients after abdominal surgery Gastric cancer is the most frequent cancer in Korea. The incidence of adhesive bowel obstruction would be increased in patients with gastric cancer, especially associated radical lymphadenectomy. The causes of postoperative adhesive obstruction include adhesion of the wound, adhesion of small intestine to small intestine, adhesion of the small intestine to other abdominal organs, and internal hernia. Several studies reported efficacy of adhesive preventing agent after colorectal resection. Gastrectomy is associated with a high risk (incidence, 11.7%-38.5%) of bowel obstruction. To date, however, no randomized study has shown that GUARDIX-SGⓇ reduces the rate of small bowel obstruction after gastrectomy with radical lymphadenectomy for gastric cancer.

Interventions

Sponsors

The Catholic University of Korea
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients with gastric adenocarcinoma who scheduled to undergo open gastrectomy * Informed consents

Exclusion criteria

* Pregnant * Ascites * Liver dysfunction * Renal failure * Past history of abdominal operation or small bowel obstruction

Design outcomes

Primary

MeasureTime frameDescription
incidence of adhesive intestinal obstructionup to 1 years after operation (every 3 month)the incidence of adhesive bowel obstruction between using GUARDIX-SG group and control group

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026